Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsBusinessMarketsPharma Q2 preview: Growth moderates amid weak domestic sales, but US to sustain strong momentum

    Pharma Q2 preview: Growth moderates amid weak domestic sales, but US to sustain strong momentum

    Drugmakers are set to gain from the continuing benefits of Revlimid and other key launches as well as easing price pressure in the US market.

    Vaibhavi Ranjan
    October 18, 2023 / 15:55 IST
    Strong US momentum to safeguard earnings for most pharma companies even as domestic sales falter in Q2.
    • PRO Panorama

      Moneycontrol Pro Panorama | After a turbulent 2025 for stock markets, will 2026 bring cheer?

      Nov 11, 2025 / 03:24 PM IST

      In November 11 edition of Moneycontrol Pro Panorama: Amid EC’s second phase of SIR legal challenges intensify, the US is wooing ...

      Read Now
    Unlock This Article

    Are you a PRO subscriber? Sign In

    What Do You Get

    • Ad free Experience

      Seamless navigation, faster responses.

    • Expert Perspective

      Explore 230+ exclusive editorials every month

    • +

      Uncover Insights from World-Renowned Experts and Journalists

    • Actionable Insights

      40+ weekly investment ideas + 3 to 4 daily technical calls

    • Virtual Events

      Exclusive Live Webinars for Expert Trading & Investment Strategies!

    • Newsletters

      Stay ahead with daily and weekly insights

    View Offers

    Unlock exclusive discounts